It’s the ultimate irony; when it comes to the important aspect of securing patient adherence, pharmaceutical companies are, too often, not patient enough.
Like the hard-earned patients they are desperate to retain, many companies’ adherence strategies fail to complete the course.
The long-term wait for demonstrable outcomes is, frequently, too bitter a pill to swallow. But there are compelling reasons why patient adherence programmes are worth the long-term investment.
A 2005 New England Journal of Medicine article that explored medicine adherence drew a simple, if obvious, conclusion: “Drugs don’t work in patients who don’t take them.”
But aside from the inherent improvements in health outcomes, adherence programmes can also help reduce the strain on healthcare resources, improve the quality and efficiency of care and underline the value of medicines by ensuring real world outcomes match clinical trial findings.
And for pharma, they can help companies minimise the significant lost revenues that avoidable non-adherence naturally causes.
View: The Adherence Construct
So how can pharma take patient support programmes to the next level – and deliver Patient Adherence 2.0 solutions that flourish in the modern age?
Find out in this exclusive PME supplement, produced in association with RAPP.
